219 related articles for article (PubMed ID: 25340791)
1. FHIT suppresses epithelial-mesenchymal transition (EMT) and metastasis in lung cancer through modulation of microRNAs.
Suh SS; Yoo JY; Cui R; Kaur B; Huebner K; Lee TK; Aqeilan RI; Croce CM
PLoS Genet; 2014 Oct; 10(10):e1004652. PubMed ID: 25340791
[TBL] [Abstract][Full Text] [Related]
2. c-Myc suppresses microRNA-29b to promote tumor aggressiveness and poor outcomes in non-small cell lung cancer by targeting FHIT.
Wu DW; Hsu NY; Wang YC; Lee MC; Cheng YW; Chen CY; Lee H
Oncogene; 2015 Apr; 34(16):2072-82. PubMed ID: 24909176
[TBL] [Abstract][Full Text] [Related]
3. Expressions of miR-30c and let-7a are inversely correlated with HMGA2 expression in squamous cell carcinoma of the vulva.
Agostini A; Brunetti M; Davidson B; Trope CG; Heim S; Panagopoulos I; Micci F
Oncotarget; 2016 Dec; 7(51):85058-85062. PubMed ID: 27835588
[TBL] [Abstract][Full Text] [Related]
4. Fhit regulates EMT targets through an EGFR/Src/ERK/Slug signaling axis in human bronchial cells.
Joannes A; Grelet S; Duca L; Gilles C; Kileztky C; Dalstein V; Birembaut P; Polette M; Nawrocki-Raby B
Mol Cancer Res; 2014 May; 12(5):775-83. PubMed ID: 24464917
[TBL] [Abstract][Full Text] [Related]
5. Fragile histidine triad gene inactivation in lung cancer: the European Early Lung Cancer project.
Verri C; Roz L; Conte D; Liloglou T; Livio A; Vesin A; Fabbri A; Andriani F; Brambilla C; Tavecchio L; Calarco G; Calabrò E; Mancini A; Tosi D; Bossi P; Field JK; Brambilla E; Sozzi G;
Am J Respir Crit Care Med; 2009 Mar; 179(5):396-401. PubMed ID: 19096006
[TBL] [Abstract][Full Text] [Related]
6. miR‑485‑5p inhibits bladder cancer metastasis by targeting HMGA2.
Chen Z; Li Q; Wang S; Zhang J
Int J Mol Med; 2015 Oct; 36(4):1136-42. PubMed ID: 26239806
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-98-HMGA2-POSTN signal pathway reverses epithelial-to-mesenchymal transition in laryngeal squamous cell carcinoma.
Zhu M; Zhang C; Chen D; Chen S; Zheng H
Biomed Pharmacother; 2019 Sep; 117():108998. PubMed ID: 31207579
[TBL] [Abstract][Full Text] [Related]
8. microRNA-214 promotes epithelial-mesenchymal transition and metastasis in lung adenocarcinoma by targeting the suppressor-of-fused protein (Sufu).
Long H; Wang Z; Chen J; Xiang T; Li Q; Diao X; Zhu B
Oncotarget; 2015 Nov; 6(36):38705-18. PubMed ID: 26462018
[TBL] [Abstract][Full Text] [Related]
9. Long non-coding RNA PRNCR1 modulates non-small cell lung cancer cell proliferation, apoptosis, migration, invasion, and EMT through PRNCR1/miR-126-5p/MTDH axis.
Guo R; Hu T; Liu Y; He Y; Cao Y
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 31912882
[TBL] [Abstract][Full Text] [Related]
10. Fhit, a tumor suppressor protein, induces autophagy via 14-3-3τ in non-small cell lung cancer cells.
Lee TG; Jeong EH; Kim SY; Kim HR; Kim H; Kim CH
Oncotarget; 2017 May; 8(19):31923-31937. PubMed ID: 28404875
[TBL] [Abstract][Full Text] [Related]
11. AEG-1 3'-untranslated region functions as a ceRNA in inducing epithelial-mesenchymal transition of human non-small cell lung cancer by regulating miR-30a activity.
Liu K; Guo L; Guo Y; Zhou B; Li T; Yang H; Yin R; Xi T
Eur J Cell Biol; 2015 Jan; 94(1):22-31. PubMed ID: 25484183
[TBL] [Abstract][Full Text] [Related]
12. MCRS1 overexpression, which is specifically inhibited by miR-129*, promotes the epithelial-mesenchymal transition and metastasis in non-small cell lung cancer.
Liu MX; Zhou KC; Cao Y
Mol Cancer; 2014 Nov; 13():245. PubMed ID: 25373388
[TBL] [Abstract][Full Text] [Related]
13. Fhit loss-associated initiation and progression of neoplasia in vitro.
Karras JR; Schrock MS; Batar B; Zhang J; La Perle K; Druck T; Huebner K
Cancer Sci; 2016 Nov; 107(11):1590-1598. PubMed ID: 27513973
[TBL] [Abstract][Full Text] [Related]
14. Fhit regulates invasion of lung tumor cells.
Joannes A; Bonnomet A; Bindels S; Polette M; Gilles C; Burlet H; Cutrona J; Zahm JM; Birembaut P; Nawrocki-Raby B
Oncogene; 2010 Feb; 29(8):1203-13. PubMed ID: 19935706
[TBL] [Abstract][Full Text] [Related]
15. miR-300 inhibits epithelial to mesenchymal transition and metastasis by targeting Twist in human epithelial cancer.
Yu J; Xie F; Bao X; Chen W; Xu Q
Mol Cancer; 2014 May; 13():121. PubMed ID: 24885626
[TBL] [Abstract][Full Text] [Related]
16. Decreased fragile histidine triad gene messenger RNA expression in lung cancer.
Sasaki H; Haneda H; Yukiue H; Kobayashi Y; Yano M; Fujii Y
Clin Lung Cancer; 2006 May; 7(6):412-6. PubMed ID: 16800968
[TBL] [Abstract][Full Text] [Related]
17. Genomic imbalances are involved in miR-30c and let-7a deregulation in ovarian tumors: implications for HMGA2 expression.
Agostini A; Brunetti M; Davidson B; Tropé CG; Heim S; Panagopoulos I; Micci F
Oncotarget; 2017 Mar; 8(13):21554-21560. PubMed ID: 28423547
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the prognostic value of methylation status and expression levels of FHIT, GSTP1 and p16 in non-small cell lung cancer in Egyptian patients.
Haroun RA; Zakhary NI; Mohamed MR; Abdelrahman AM; Kandil EI; Shalaby KA
Asian Pac J Cancer Prev; 2014; 15(10):4281-7. PubMed ID: 24935385
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-33a mediates the regulation of high mobility group AT-hook 2 gene (HMGA2) by thyroid transcription factor 1 (TTF-1/NKX2-1).
Rice SJ; Lai SC; Wood LW; Helsley KR; Runkle EA; Winslow MM; Mu D
J Biol Chem; 2013 Jun; 288(23):16348-16360. PubMed ID: 23625920
[TBL] [Abstract][Full Text] [Related]
20. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation.
Wali A; Srinivasan R; Shabnam MS; Majumdar S; Joshi K; Behera D
Mol Cancer Res; 2006 Feb; 4(2):93-9. PubMed ID: 16513840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
